Hybrid promoters directed tBid gene expression to breast cancer cells by transcriptional targeting

Biotechnology Progress

Volumn 26, Issue 2, 2010, Pages 505-511

  Farokhimanesh, Samila ^a   Rahbarizadeh, Fatemeh ^a   Rasaee, Mohammad J ^a   Kamali, Abbas ^b   Mashkani, Baratali ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Apoptosis; Cancer and hypoxia; Gene therapy; Hybrid promoter; Tbid

Indexed keywords

ACTIVITY ASSAYS; AFTER-TREATMENT; APOPTOSIS; BCL-2 FAMILY; BREAST CANCER CELLS; CANCER CELL LINES; CANCER CELLS; CANCER GENE THERAPY; CASPASE-3; CMV PROMOTER; CORE PROMOTERS; HYBRID PROMOTER; MICROENVIRONMENTS; NORMAL TISSUE; PROMOTER ACTIVITIES; SURVIVIN;

CELL CULTURE; CELL DEATH; GENE THERAPY; GENETIC ENGINEERING;

GENE EXPRESSION;

BIRC5 PROTEIN, HUMAN; CASPASE 3; ESTROGEN; MICROTUBULE ASSOCIATED PROTEIN; MUC1 PROTEIN, HUMAN; MUCIN 1; PROTEIN BID;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL HYPOXIA; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BREAST NEOPLASMS; CASPASE 3; CELL HYPOXIA; CELL LINE, TUMOR; CLONING, MOLECULAR; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MUCIN-1; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

CYTOMEGALOVIRUS;

EID: 77950905875     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.353     Document Type: Article

References (44)

1. Barzon L, Boscaro M. Endocrine Aspects of Cancer Gene Therapy. Endocr Rev. 2005; 25: 1-44.
2. Lemoine NR. Understanding Gene Therapy. London: Oxford Bios Scientific; 1999.
3. Curiel DT. Cancer Gene Therapy, USA: Humanna Press; 2004.
4. Mccromick F. Cancer gene therapy: fringe or cutting edge? Nat Rev. 2001; 1: 130-141.
5. Harrington KJ, Bateman AR, Melcher AA, Ahmed A, Vile RG. Cancer gene therapy: Part 1. Vector development and regulation of gene expression. Clin Oncol. 2002; 14: 3-16.
6. Gross A, Mcdonnell JM, Korsmeyer SJ. Bcl2 family members and the mitochondria in apoptosis. Gene Dev. 1999; 13: 1899-1911.
7. Madesh M, Antonsson B, Srinivasula SM, Alnemri ES, Hajnóczky G. Rapid kinetics of tBid-induced cytochrome c and Smac/DIABLO release and mitochondrial depolarization. J Biol Chem. 2002; 277: 5651-5659.
8. Cain K, Bratton SB, Cohen GM. The Apaf-1 apoptosome: a large caspase-activating complex. Biochimie. 2002; 84: 203-214.
9. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 2002; 9: 505-512.
10. Kazhdan I, Long L, Montellano R, Cavazos DA, Marciniak RA. Targeted gene therapy for breast cancer with truncated Bid. Cancer Gene Ther. 2006; 13: 141-149.
11. Wang K, Yin XM, Chao DT. BID: a novel BH3 domain-only death agonist. Genes Dev. 1996; 10: 2859-2869.
12. Luo X, Budlhardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998; 94: 481-490.
13. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998; 94: 491-501.
14. Harrington KJ, Linardakis E, Vile RG. Transcriptional control: an essential component of cancer gene therapy strategies?. Adv Drug Deliv Rev. 2000; 44: 167-84.
15. Nettelbeck DM, Jérôme V, Müller R. Gene therapy: designer promoters for tumour targeting. Trends Genet. 2000; 16: 174-181.
16. Kufe D, Inghirami G, Abe M, Hayes D, Justi WH, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984; 3: 223-232.
17. Ohuchi N, Page DL, Merino MJ, Viglione MJ, Kufe DW, Schlom J. Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast. J Natl Cancer Inst. 1987; 79: 109-117.
18. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000; 6: 127-134.
19. Kovarik A, Peat N, Wilson D, Gendler SJ, Taylor PJ. Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem. 1993; 268: 9917-9926.
20. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999; 2: 305-311.
21. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000; 157: 411-421.
22. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 2000; 7: 493-498.
23. Valavaara R. Reliability of estrogen receptors in predicting response to antiestrogens. Oncology (Williston Park). 1997; 11: 14-18.
24. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002; 277: 3247-3257.
25. Harms JS, Eakle KA, Kuo LS, Bremel RD, Splitter GA. Comparison of bovine leukemia virus (BLV) and CMV promoter-driven reporter gene expression in BLV- infected and non-infected cells. Genet Vaccines Ther. 2004; 24: 11-19.
26. Devine PL, Birrell GW, Whitehead RH, Harada H, Xing PX, Mckenzie IF. Expression of MUC1 and MUC2 mucins by human tumor cell lines. Tumour Biol. 1992; 13: 268-77.
27. Lacunza E, Abba MC, Segal-Eiras A, Croce MV. Identification and expression of the epithelial Muc1 mucin in normal feline tissues. Vet Immunol Immunopathol. 2009; 15: 17-24.
28. Hanisch FG, Stadie TR, Deutzmann F, Peter-Katalinic J. MUC1 glycoforms in breast cancer-cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation. Eur J Biochem. 1996; 15: 318-327.
29. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov. 2002; 11: 111-121.
30. Zangemeister WU, Leech SH, Olie RA, Simoes AP, Gautschi O, Luedke GH, Natt F, Haner R, Martin P, Hall J, Nalin CM, Stahel RA. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res. 2000; 6: 2547-2555.
31. Weaver KD, Yeyeodu S, Cusack JC, Baldwin AS, Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. Neuro Oncol. 2003; 61: 187-196.
32. Marcelli M, Cunningham GR, Walkup M, He Z, Sturgis L, Kagan C, Mannucci R, Nicoletti I, Teng B, Denner L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 1999; 59: 382-390.
33. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 2000; 60: 1645-1653.
34. Tsuruta Y, Mandai M, Konishi I, Kuroda H, Kusakari T, Yura Y, Hamid AA, Tamura I, Kariya M, Fujii S. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. Eur J Cancer. 2001; 37: 531-541.
35. Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, Hung MC. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res. 2002; 62: 8-12.
36. Hernandez AR, Pihalja M, Nunez G, Clarke MF. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther. 2001; 8: 298-307.
37. Wu L. Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med. 2003; 9: 421-430.
38. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, Lemoine NR. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol. 1999; 17: 2180-2180.
39. Wang X, Southard RC, Kilgore MW. The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Cancer Res. 2004; 64: 5592-5596.
40. Li X, Zhang J, Gao H, Vieth E, Bae KH, Zhang YP, Lee SJ, Raikwar S, Gardner TA, Hutchins GD, Vander PD, Kao C, Jeng MH. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter. Mol Cancer Ther. 2005; 4: 1850-1859.
41. Shi CX, Graham FL, Hitt MM. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter. J Gene Med. 2006; 8: 442-451.
42. Chung I, Schwartz PE, Crystal RG, Pizzorno G, Leavitt J, Deisseroth AB. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther. 1999; 6: 99-106.
43. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59: 5830-5835.
44. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997; 94: 8104-8109.